Robert Taub

Entrepreneur and angel investor with a focus on biopharmaceutical and medical technology companies, with significant involvement in the Israeli startup ecosystem.

Angel Investor Active Liège, Belgium
Last updated 2026-07-20
Portfolio
1
in our dataset
Rounds participated
1
Rounds led
0
Rounds' value
$1.0M
total disclosed, rounds participated
Stages
—

About

Robert Taub is a serial entrepreneur and angel investor with over four decades of experience in the biopharmaceutical and medical technology industries. He co-founded Octapharma AG in 1983 and founded Omrix Biopharmaceuticals in 1995, which was later acquired by Johnson & Johnson. In 2009, he co-founded Nyxoah S.A., a company developing implantable devices for the treatment of obstructive sleep apnea. He has a demonstrated track record of founding companies with R&D in Israel and investing in Israeli startups like GuardKnox, LifeBond, NeuroDerm, and Archimedicx.

Portfolio · 1

ARCHIMEDICX
Hospital Search, Ranking, and Booking System
1 round $1.0M committed

Investment activity

2 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences3

Q&A

What is Robert Taub's primary investment focus by sector?
Robert Taub primarily focuses on the Health Tech & Life Sciences sector, with all three of his portfolio companies and two exits being in this area.
Can you name some of Robert Taub's notable portfolio companies?
Robert Taub's notable portfolio companies include ARCHIMEDICX, which offers a hospital search, ranking, and booking system, and Nyxoah, focused on hypoglossal nerve stimulation therapy.
Which of Robert Taub's portfolio companies have had a public exit?
Robert Taub has seen two portfolio companies go public: Nyxoah in September 2020 on Euronext with a valuation of $423M, and NeuroDerm in November 2014 on NASDAQ with a valuation of $164M.
What is Robert Taub's investment stage preference?
Robert Taub has invested across various stages, including Seed, A Round, and B Round.
What kind of business models do Robert Taub's portfolio companies typically have?
Robert Taub's portfolio companies, such as ARCHIMEDICX, engage in both B2B and B2C business models, while others like NeuroDerm and Nyxoah focus on B2B.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Radar intelligence

Patents

EPO17